key: cord-0844067-24ocjyz6
authors: de Paula, Camila Sanson Yoshino; Palandri, Giovanna Gavros; Fonseca, Taiane Siraisi; Vendramini, Thaís Cristina Annibale; Farhat, Sylvia Costa Lima; Pereira, Maria Fernanda Badue; Litvinov, Nadia; Toma, Ricardo Katsuya; de Sá, Fernanda Viveiros Moreira; Rodrigues, Katharina Reichmann; Schvartsman, Cláudio; Forsait, Silvana; Sakita, Neusa Keico; Kanunfre, Kelly Aparecida; Rocha, Mussya Cisotto; dos Santos, Emilly Henrique; Okay, Thelma Suely; Pinho, João Renato Rebello; de Carvalho, Werther Brunow; Carneiro-Sampaio, Magda; Silva, Clovis Artur A.; Marques, Heloisa Helena de Sousa
title: Gastrointestinal manifestations are associated with severe pediatric COVID-19: a study in tertiary hospital
date: 2021-04-30
journal: J Infect
DOI: 10.1016/j.jinf.2021.04.030
sha: 04c26d174c76686b2489d8ea65d72a7e845bd649
doc_id: 844067
cord_uid: 24ocjyz6

nan

It is already known that the spectrum of signs and symptoms of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to fatal illness in children and adolescent 1 . The most common signs and symptoms of pediatric COVID-19 are milder as cough, sore throat and fever. In fact, Dr. Bin Zhang and colleagues reported in the Journal of Infection characteristics of 46 children hospitalized with COVID-19 and none of them had severe disease 2 . We have noticed that these children had no gastrointestinal symptoms identified. Nonetheless, manifestations as diarrhea, vomiting and abdominal pain have been described in COVID pediatric patients in up to 50% of the cases [3] [4] [5] [6] . Furthermore, a systematic review 7 showed that the gastrointestinal tract was the system more frequently associated to the multisystem inflammatory syndrome in children (MIS-C), a severe spectrum of disease in children. We evaluated 83 patients with laboratory-confirmed COVID-19, both by real-time RT-PCR exam and serological test and we aimed to compare demographic and anthropometric data, underlying conditions, clinical characteristics, exams, treatments, and outcomes in laboratory-confirmed pediatric COVID-19 patients with and without gastrointestinal signs and symptoms. Patients were enrolled from April to September of 2020, in a tertiary and university hospital in São Paulo, Brazil.

We defined gastrointestinal involvement of pediatric COVID-19 required at least one of the following manifestations: diarrhea, abdominal pain or vomiting 8 .

Stool culture and Clostridioides difficile stool toxin were also evaluated in patients with diarrhea. Nausea, upper and lower gastrointestinal bleeding were recorded. Gastrointestinal endoscopy, colonoscopy, abdominal computed tomography and abdominal ultrasonography were also analyzed. None of pediatric COVID-19 patients with diarrhea reported recent antibiotic use. MIS-C was diagnosed according to Center for Disease Control (CDC) criteria 9 . In six patients, stool samples were obtained, and a molecular method was performed to assess the presence of SARS-CoV-2 in feces. Using a molecular method, the presence of SARS-CoV-2 in feces was performed in six patients. In two stool samples the virus was detected, in two the molecular test were negative and inconclusive results were observed in another two patients. The two children that had detection of SARS-CoV-2 in feces were under the age of one year and had preexisting chronic disease (Down´s syndrome and renal rhabdoid tumor, respectively). One of them presented vomiting. No one had diarrhea or abdominal pain. On the other hand, the two patients with no detection of the virus in the feces were older than 10 years and one had nausea, vomiting, diarrhea and abdominal pain.

The present study showed that laboratory-confirmed COVID-19 pediatric patients with gastrointestinal manifestations, particularly vomiting, had a severe systemic involvement and high mortality rate. Moreover, cardiac abnormalities were a relevant finding in this setting.

We extended previous report of laboratory-confirmed pediatric COVID-19 with at least one gastrointestinal sign/symptom demonstrating that cardiac abnormalities and hyperinflammation may occur in these patients 4, 7 . Indeed, Belhadjer et al., reported that the vast majority of 35 pediatric COVID-19 patients with severe cardiac involvement had at least one gastrointestinal manifestation (diarrhea, abdominal pain or vomiting) 8 .

In this study the number of organs and systems involvement, intravenous immunoglobulin and aspirin were more frequently observed in patients with digestive signs/symptoms. These findings support the idea that the involvement of the gastrointestinal tract may be an expression of systemic disease and hyperinflammation.

The mortality rate in this study was 7%. The high frequency of chronic and immunosuppressed conditions in our laboratory-confirmed pediatric COVID-19 population may contribute to high lethality.

We also confirmed previous reports that gastrointestinal involvement had high levels of serum biomarkers, indicating acute inflammation, predominantly with increase of fibrinogen and D-dimer parameters. The elevated levels of these parameters have been also correlated with cytokine storm, multi-organ dysfunction and unfavorable outcome in severe patients with COVID-19 10 .

Further studies with a systematic analysis of pro-inflammatory and antiinflammatory cytokines profile, and lymphocyte subpopulations will be necessary in laboratory-confirmed pediatric COVID-19 populations to clarify these findings.

In conclusion, pediatric COVID-19 patients, mainly in those with underlying conditions and gastrointestinal manifestations, may have a severe and systemic involvement, with high mortality rate. Therefore, our study suggested that laboratory-confirmed COVID-19 pediatric patients with digestive signs/symptoms require attention for hyperinflammation condition and cardiac abnormalities. Results are presented in n (%), median (minimum-maximum values), mean ± standard deviation. 

The challenging and unpredictable spectrum of COVID-19 in children and adolescents

Children hospitalized for coronavirus disease 2019 (COVID-19): A multicenter retrospective descriptive study

Coronavirus Disease 2019 in Children -United States

Gastrointestinal Symptoms in Severe COVID-19 Children

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

Gastrointestinal manifestations and nutritional therapy during COVID-19 pandemic: a practical guide for pediatricians. Einstein (Sao Paulo)

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C)

The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis